Monopar ALXN1840 Phase 3 Data Improves Wilson Disease Outcomes
Wilmette, Illinois, USA, April 19, 2026 In a significant advancement for rare disease therapeutics, Monopar Therapeutics Inc. has presented...
AAN 2026
Advertisement
Monopar Reports Phase 3 ALXN1840 Data at AAN 2026
WILMETTE, Ill., April 19, 2026 Monopar Therapeutics announced new Phase 3 clinical data demonstrating greater neurologic benefit of ALXN1840...
Neurelis Shows Strong Seizure Control Data for VALTOCO at AAN
SAN DIEGO, Calif., April 16, 2026 Neurelis, Inc. has announced new clinical and real-world analyses demonstrating the effectiveness of...
Jazz Pharmaceuticals Presents Neurology Drug Data at AAN
DUBLIN, Ireland, April 9, 2026 Jazz Pharmaceuticals plc has announced the presentation of six scientific abstracts, including one oral...
Rapport Presents Phase 2 Data for Epilepsy Drug RAP-219
BOSTON & SAN DIEGO, USA — April 1, 2026 Rapport Therapeutics, Inc. announced that it will present new Phase...
Advertisement
